BioNTech and Medigene Collaborate on Cancer Therapy
Two German biotechs, RNA vaccines specialist BioNTech and Medigene, a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, have entered a three-year multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer.
